WallStSmart

Abbott Laboratories (ABT)vsIntelligent Bio Solutions Inc. (INBS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 1237663% more annual revenue ($44.33B vs $3.58M). ABT leads profitability with a 14.7% profit margin vs 0.0%. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

INBS

Hold

40

out of 100

Grade: D

Growth: 6.3Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued

Intrinsic value data unavailable for INBS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

INBS2 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
47.6%10/10

Revenue surging 47.6% year-over-year

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

INBS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.50M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-1.5%2/10

ROE of -1.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : INBS

The strongest argument for INBS centers on Price/Book, Revenue Growth. Revenue growth of 47.6% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : INBS

The primary concerns for INBS are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ABT profiles as a value stock while INBS is a hypergrowth play — different risk/reward profiles.

INBS carries more volatility with a beta of 4.63 — expect wider price swings.

INBS is growing revenue faster at 47.6% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (51/100 vs 40/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Intelligent Bio Solutions Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Intelligent Bio Solutions Inc. (INBS) is a forward-thinking biotechnology company committed to revolutionizing healthcare through the development of innovative diagnostic solutions and biomarker-driven technologies, especially in the realm of drug abuse testing and monitoring. Leveraging cutting-edge scientific advancements, the company aims to enhance healthcare outcomes by offering highly accurate and rapid-testing methodologies that facilitate timely clinical decision-making. Positioned strategically at the nexus of technology and healthcare, INBS is well-positioned to capitalize on the growing demand for advanced diagnostic tools in a dynamic market landscape.

Want to dig deeper into these stocks?